HC Wainwright Reaffirms "Buy" Rating for Oculis (NASDAQ:OCS)

Oculis (NASDAQ:OCS - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a report released on Wednesday, Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright's price target points to a potential upside of 84.50% from the company's previous close.

Oculis Stock Up 2.8 %

Shares of Oculis stock traded up $0.45 during trading hours on Wednesday, reaching $16.26. 71,531 shares of the company's stock were exchanged, compared to its average volume of 34,846. The stock has a market cap of $658.60 million, a P/E ratio of -9.13 and a beta of 0.30. The company has a 50 day moving average of $12.81 and a two-hundred day moving average of $12.18. The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01. Oculis has a fifty-two week low of $9.05 and a fifty-two week high of $16.70.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The company had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. On average, sell-side analysts forecast that Oculis will post -2.19 EPS for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.